FibroBiologics, Inc. 8-K

What Happened

• FibroBiologics, Inc. (FBLG) filed an 8-K on January 2, 2026 disclosing that Nasdaq notified the company on July 1, 2025 that its common stock closed below the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2) for a 30‑day period. Nasdaq gave the company a 180‑calendar‑day cure period that expired December 29, 2025.
• On December 30, 2025 Nasdaq informed the company it planned to delist the securities for continued non‑compliance unless the company timely requests a hearing before the Nasdaq Hearings Panel. The company says it will timely request a hearing (which stays delisting pending the hearing and any Panel extension) and will monitor its bid price and evaluate options to regain compliance.
• As a concrete step, the company filed definitive proxy materials on December 29, 2025 asking shareholders to approve a reverse stock split at a ratio between 1‑for‑5 and 1‑for‑30 (final ratio to be set by the board).

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) — $1.00 minimum bid price.
• Cure period: 180 calendar days, ending December 29, 2025; second notice received December 30, 2025.
• Reverse split proposal: shareholder vote requested for a ratio between 1-for-5 and 1-for-30 (board to determine exact ratio).
• 8-K filing date: January 2, 2026.

Why It Matters

• Delisting risk: If Nasdaq proceeds and the company is delisted, FBLG could lose its Nasdaq listing, which can reduce liquidity, limit investor access, and potentially lower the stock price.
• Possible remedies: A successful hearing or a reverse stock split that raises the per‑share bid above $1 could preserve the Nasdaq listing; however, the company expressly warns there is no assurance that any action will succeed.
• Near-term focus for investors: watch for the outcome of the Nasdaq hearing, any Panel extension, the shareholder vote on the reverse split, and subsequent changes in the stock’s closing bid price.